This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chi, D. D. Articles by Hoon, D. S. Search for Related Content PubMed PubMed Citation Articles by Chi, D. D. Articles by Hoon, D. S.

American Journal of Pathology, Vol 150, 2143-2152, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas

DD Chi, RE Merchant, R Rand, AJ Conrad, D Garrison, R Turner, DL Morton and DS Hoon
National Genetics Institute, Los Angeles, California, USA.

Both melanocytes and glial cells are derived embryologically from the neural ectoderm. Their malignant transformed counterparts, melanoma and glioma cells, respectively, may share common antigens. Numerous tumor- associated antigens have been identified in melanomas but only a few a gliomas. Using an established reverse transcriptase polymerase chain reaction plus Southern blot assay, we compared the mRNA expression of melanoma-associated antigens (MAAs) of melanomas to brain tumors primarily derived from glial cells. The MAAs studied included tyrosinase (Tyr), tyrosinase-related protein-1 and -2 (TRP-1 and TRP- 2), gp100, human melanoma antigen-encoding genes 1 and 3 (MAGE-1 and MAGE-3), and melanotransferrin (p97). Glioblastoma multiforme (n = 21), anaplastic astrocytoma (n = 3), ependymoma (n = 2), meningioma (n = 3), oligodendroglioma (n = 1), and melanoma (n = 12) tumor specimens were assayed for MAA mRNA expression. Glioblastoma multiforme, astrocytoma, and melanoma cell lines were also assayed. We observed that individual MAA mRNAs were expressed in these brain tumors and cell lines at varying frequencies. The melanogenesis-pathway-related MAAs Tyr, TRP-1, TRP-2, and gp100 mRNAs were also expressed at different levels in normal brain tissues but at a much lower frequency than in glioblastoma multiforme and melanoma. MAGE-1 and MAGE-3 mRNA were expressed in different types of tumor specimens and cell lines but never in normal brain tissue. Tumor antigen p97 was expressed in all types of tumors and also in normal brain tissues. These studies demonstrate that melanomas and primary brain tumors express common MAAs and could be exploited in patients with malignant glioma by active specific immunotherapy against these common MAAs.

This article has been cited by other articles:

				J. G. Zhang, J. Eguchi, C. A. Kruse, G. G. Gomez, H. Fakhrai, S. Schroter, W. Ma, N. Hoa, B. Minev, C. Delgado, et al. Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell-Based Therapeutics Clin. Cancer Res., January 15, 2007; 13(2): 566 - 575. [Abstract] [Full Text] [PDF]

				J. Tang, P. Flomenberg, L. Harshyne, L. Kenyon, and D. W. Andrews Glioblastoma Patients Exhibit Circulating Tumor-Specific CD8+ T Cells Clin. Cancer Res., July 15, 2005; 11(14): 5292 - 5299. [Abstract] [Full Text] [PDF]

				H. N. Abrahamsen, B. Sandahl Sorensen, E. Nexo, S. J. Hamilton-Dutoit, J. Larsen, and T. Steiniche Pathologic Assessment of Melanoma Sentinel Nodes: A Role for Molecular Analysis Using Quantitative Real-Time Reverse Transcription-PCR for MART-1 and Tyrosinase Messenger RNA Clin. Cancer Res., February 15, 2005; 11(4): 1425 - 1433. [Abstract] [Full Text] [PDF]

				H. H. Steiner, M. M. Bonsanto, P. Beckhove, M. Brysch, K. Geletneky, R. Ahmadi, R. Schuele-Freyer, P. Kremer, G. Ranaie, D. Matejic, et al. Antitumor Vaccination of Patients With Glioblastoma Multiforme: A Pilot Study to Assess Feasibility, Safety, and Clinical Benefit J. Clin. Oncol., November 1, 2004; 22(21): 4272 - 4281. [Abstract] [Full Text] [PDF]

				G. Liu, H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells Cancer Res., July 15, 2004; 64(14): 4980 - 4986. [Abstract] [Full Text] [PDF]

				R. M. Prins, S. K. Odesa, and L. M. Liau Immunotherapeutic Targeting of Shared Melanoma-Associated Antigens in a Murine Glioma Model Cancer Res., December 1, 2003; 63(23): 8487 - 8491. [Abstract] [Full Text] [PDF]

				D. Ribuffo, A. Gradilone, M. Vonella, S. Chiummariello, E. Cigna, N. Haliassos, R. Massa, I. Silvestri, S. Calvieri, L. Frati, et al. Prognostic Significance of Reverse Transcriptase-Polymerase Chain Reaction-Negative Sentinel Nodes in Malignant Melanoma Ann. Surg. Oncol., May 1, 2003; 10(4): 396 - 402. [Abstract] [Full Text] [PDF]

				H. Takeuchi, C. Kuo, D. L. Morton, H.-J. Wang, and D. S. B. Hoon Expression of Differentiation Melanoma-associated Antigen Genes Is Associated with Favorable Disease Outcome in Advanced-Stage Melanomas Cancer Res., January 15, 2003; 63(2): 441 - 448. [Abstract] [Full Text] [PDF]

				M. H. Chung, R. K. Gupta, E. Hsueh, R. Essner, W. Ye, R. Yee, and D. L. Morton Humoral Immune Response to a Therapeutic Polyvalent Cancer Vaccine After Complete Resection of Thick Primary Melanoma and Sentinel Lymphadenectomy J. Clin. Oncol., January 15, 2003; 21(2): 313 - 319. [Abstract] [Full Text] [PDF]

				J. S. Yu, C. J. Wheeler, P. M. Zeltzer, H. Ying, D. N. Finger, P. K. Lee, W. H. Yong, F. Incardona, R. C. Thompson, M. S. Riedinger, et al. Vaccination of Malignant Glioma Patients with Peptide-pulsed Dendritic Cells Elicits Systemic Cytotoxicity and Intracranial T-cell Infiltration Cancer Res., February 1, 2001; 61(3): 842 - 847. [Abstract] [Full Text]

				U. Sahin, M. Koslowski, O. Türeci, T. Eberle, C. Zwick, B. Romeike, J.-R. Moringlane, K. Schwechheimer, W. Feiden, and M. Pfreundschuh Expression of Cancer Testis Genes in Human Brain Tumors Clin. Cancer Res., October 1, 2000; 6(10): 3916 - 3922. [Abstract] [Full Text]

				P. J. Bostick, D. L. Morton, R. R. Turner, K. T. Huynh, H.-J. Wang, R. Elashoff, R. Essner, and D. S.B. Hoon Prognostic Significance of Occult Metastases Detected by Sentinel Lymphadenectomy and Reverse Transcriptase–Polymerase Chain Reaction in Early-Stage Melanoma Patients J. Clin. Oncol., October 1, 1999; 17(10): 3238 - 3244. [Abstract] [Full Text] [PDF]

				D. L. Scarcella, C. W. Chow, M. F. Gonzales, C. Economou, F. Brasseur, and D. M. Ashley Expression of MAGE and GAGE in High-Grade Brain Tumors: A Potential Target for Specific Immunotherapy and Diagnostic Markers Clin. Cancer Res., February 1, 1999; 5(2): 335 - 341. [Abstract] [Full Text] [PDF]